Correlation of radiographic progression with the cumulative activity of synovitis estimated by power Doppler ultrasound in rheumatoid arthritis: difference between patients treated with methotrexate and those treated with biological agents.
Identifieur interne : 001560 ( PubMed/Curation ); précédent : 001559; suivant : 001561Correlation of radiographic progression with the cumulative activity of synovitis estimated by power Doppler ultrasound in rheumatoid arthritis: difference between patients treated with methotrexate and those treated with biological agents.
Auteurs : Kei Ikeda [Japon] ; Daiki Nakagomi ; Yoshie Sanayama ; Mieko Yamagata ; Ayako Okubo ; Taro Iwamoto ; Hirotoshi Kawashima ; Kentaro Takahashi ; Hiroshi NakajimaSource :
- The Journal of rheumatology [ 0315-162X ] ; 2013.
Descripteurs français
- KwdFr :
- Adalimumab, Adulte, Adulte d'âge moyen, Anticorps monoclonaux (usage thérapeutique), Anticorps monoclonaux humanisés (usage thérapeutique), Antirhumatismaux (usage thérapeutique), Arthrographie (), Biais de l'observateur, Facteur de nécrose tumorale alpha (antagonistes et inhibiteurs), Femelle, Humains, Immunoglobuline G (usage thérapeutique), Infliximab, Mâle, Méthotrexate (usage thérapeutique), Polyarthrite rhumatoïde (imagerie diagnostique), Polyarthrite rhumatoïde (traitement médicamenteux), Récepteurs aux facteurs de nécrose tumorale (usage thérapeutique), Sensibilité et spécificité, Sujet âgé, Synovite (imagerie diagnostique), Synovite (traitement médicamenteux), Échographie-doppler (), Étanercept, Études prospectives, Évolution de la maladie.
- MESH :
- antagonistes et inhibiteurs : Facteur de nécrose tumorale alpha.
- imagerie diagnostique : Polyarthrite rhumatoïde, Synovite.
- traitement médicamenteux : Polyarthrite rhumatoïde, Synovite.
- usage thérapeutique : Anticorps monoclonaux, Anticorps monoclonaux humanisés, Antirhumatismaux, Immunoglobuline G, Méthotrexate, Récepteurs aux facteurs de nécrose tumorale.
- Adalimumab, Adulte, Adulte d'âge moyen, Arthrographie, Biais de l'observateur, Femelle, Humains, Infliximab, Mâle, Sensibilité et spécificité, Sujet âgé, Échographie-doppler, Étanercept, Études prospectives, Évolution de la maladie.
English descriptors
- KwdEn :
- Adalimumab, Adult, Aged, Antibodies, Monoclonal (therapeutic use), Antibodies, Monoclonal, Humanized (therapeutic use), Antirheumatic Agents (therapeutic use), Arthritis, Rheumatoid (diagnostic imaging), Arthritis, Rheumatoid (drug therapy), Arthrography (methods), Arthrography (statistics & numerical data), Disease Progression, Etanercept, Female, Humans, Immunoglobulin G (therapeutic use), Infliximab, Male, Methotrexate (therapeutic use), Middle Aged, Observer Variation, Prospective Studies, Receptors, Tumor Necrosis Factor (therapeutic use), Sensitivity and Specificity, Synovitis (diagnostic imaging), Synovitis (drug therapy), Tumor Necrosis Factor-alpha (antagonists & inhibitors), Ultrasonography, Doppler (methods), Ultrasonography, Doppler (statistics & numerical data).
- MESH :
- chemical , antagonists & inhibitors : Tumor Necrosis Factor-alpha.
- chemical , therapeutic use : Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Immunoglobulin G, Methotrexate, Receptors, Tumor Necrosis Factor.
- chemical : Adalimumab, Etanercept, Infliximab.
- diagnostic imaging : Arthritis, Rheumatoid, Synovitis.
- drug therapy : Arthritis, Rheumatoid, Synovitis.
- methods : Arthrography, Ultrasonography, Doppler.
- statistics & numerical data : Arthrography, Ultrasonography, Doppler.
- Adult, Aged, Disease Progression, Female, Humans, Male, Middle Aged, Observer Variation, Prospective Studies, Sensitivity and Specificity.
Abstract
Our prospective study aimed to demonstrate that the cumulative synovial power Doppler (PD) ultrasound scores correlate with radiographic progression better than conventional measures in patients with rheumatoid arthritis (RA). We also investigated the difference between antirheumatic agents.
DOI: 10.3899/jrheum.130556
PubMed: 24187096
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001560
Links to Exploration step
pubmed:24187096Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Correlation of radiographic progression with the cumulative activity of synovitis estimated by power Doppler ultrasound in rheumatoid arthritis: difference between patients treated with methotrexate and those treated with biological agents.</title><author><name sortKey="Ikeda, Kei" sort="Ikeda, Kei" uniqKey="Ikeda K" first="Kei" last="Ikeda">Kei Ikeda</name><affiliation wicri:level="1"><nlm:affiliation>From the Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>From the Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba</wicri:regionArea></affiliation></author><author><name sortKey="Nakagomi, Daiki" sort="Nakagomi, Daiki" uniqKey="Nakagomi D" first="Daiki" last="Nakagomi">Daiki Nakagomi</name></author><author><name sortKey="Sanayama, Yoshie" sort="Sanayama, Yoshie" uniqKey="Sanayama Y" first="Yoshie" last="Sanayama">Yoshie Sanayama</name></author><author><name sortKey="Yamagata, Mieko" sort="Yamagata, Mieko" uniqKey="Yamagata M" first="Mieko" last="Yamagata">Mieko Yamagata</name></author><author><name sortKey="Okubo, Ayako" sort="Okubo, Ayako" uniqKey="Okubo A" first="Ayako" last="Okubo">Ayako Okubo</name></author><author><name sortKey="Iwamoto, Taro" sort="Iwamoto, Taro" uniqKey="Iwamoto T" first="Taro" last="Iwamoto">Taro Iwamoto</name></author><author><name sortKey="Kawashima, Hirotoshi" sort="Kawashima, Hirotoshi" uniqKey="Kawashima H" first="Hirotoshi" last="Kawashima">Hirotoshi Kawashima</name></author><author><name sortKey="Takahashi, Kentaro" sort="Takahashi, Kentaro" uniqKey="Takahashi K" first="Kentaro" last="Takahashi">Kentaro Takahashi</name></author><author><name sortKey="Nakajima, Hiroshi" sort="Nakajima, Hiroshi" uniqKey="Nakajima H" first="Hiroshi" last="Nakajima">Hiroshi Nakajima</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:24187096</idno><idno type="pmid">24187096</idno><idno type="doi">10.3899/jrheum.130556</idno><idno type="wicri:Area/PubMed/Corpus">001560</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001560</idno><idno type="wicri:Area/PubMed/Curation">001560</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001560</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Correlation of radiographic progression with the cumulative activity of synovitis estimated by power Doppler ultrasound in rheumatoid arthritis: difference between patients treated with methotrexate and those treated with biological agents.</title><author><name sortKey="Ikeda, Kei" sort="Ikeda, Kei" uniqKey="Ikeda K" first="Kei" last="Ikeda">Kei Ikeda</name><affiliation wicri:level="1"><nlm:affiliation>From the Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>From the Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba</wicri:regionArea></affiliation></author><author><name sortKey="Nakagomi, Daiki" sort="Nakagomi, Daiki" uniqKey="Nakagomi D" first="Daiki" last="Nakagomi">Daiki Nakagomi</name></author><author><name sortKey="Sanayama, Yoshie" sort="Sanayama, Yoshie" uniqKey="Sanayama Y" first="Yoshie" last="Sanayama">Yoshie Sanayama</name></author><author><name sortKey="Yamagata, Mieko" sort="Yamagata, Mieko" uniqKey="Yamagata M" first="Mieko" last="Yamagata">Mieko Yamagata</name></author><author><name sortKey="Okubo, Ayako" sort="Okubo, Ayako" uniqKey="Okubo A" first="Ayako" last="Okubo">Ayako Okubo</name></author><author><name sortKey="Iwamoto, Taro" sort="Iwamoto, Taro" uniqKey="Iwamoto T" first="Taro" last="Iwamoto">Taro Iwamoto</name></author><author><name sortKey="Kawashima, Hirotoshi" sort="Kawashima, Hirotoshi" uniqKey="Kawashima H" first="Hirotoshi" last="Kawashima">Hirotoshi Kawashima</name></author><author><name sortKey="Takahashi, Kentaro" sort="Takahashi, Kentaro" uniqKey="Takahashi K" first="Kentaro" last="Takahashi">Kentaro Takahashi</name></author><author><name sortKey="Nakajima, Hiroshi" sort="Nakajima, Hiroshi" uniqKey="Nakajima H" first="Hiroshi" last="Nakajima">Hiroshi Nakajima</name></author></analytic><series><title level="j">The Journal of rheumatology</title><idno type="ISSN">0315-162X</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adalimumab</term><term>Adult</term><term>Aged</term><term>Antibodies, Monoclonal (therapeutic use)</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Antirheumatic Agents (therapeutic use)</term><term>Arthritis, Rheumatoid (diagnostic imaging)</term><term>Arthritis, Rheumatoid (drug therapy)</term><term>Arthrography (methods)</term><term>Arthrography (statistics & numerical data)</term><term>Disease Progression</term><term>Etanercept</term><term>Female</term><term>Humans</term><term>Immunoglobulin G (therapeutic use)</term><term>Infliximab</term><term>Male</term><term>Methotrexate (therapeutic use)</term><term>Middle Aged</term><term>Observer Variation</term><term>Prospective Studies</term><term>Receptors, Tumor Necrosis Factor (therapeutic use)</term><term>Sensitivity and Specificity</term><term>Synovitis (diagnostic imaging)</term><term>Synovitis (drug therapy)</term><term>Tumor Necrosis Factor-alpha (antagonists & inhibitors)</term><term>Ultrasonography, Doppler (methods)</term><term>Ultrasonography, Doppler (statistics & numerical data)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adalimumab</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Anticorps monoclonaux (usage thérapeutique)</term><term>Anticorps monoclonaux humanisés (usage thérapeutique)</term><term>Antirhumatismaux (usage thérapeutique)</term><term>Arthrographie ()</term><term>Biais de l'observateur</term><term>Facteur de nécrose tumorale alpha (antagonistes et inhibiteurs)</term><term>Femelle</term><term>Humains</term><term>Immunoglobuline G (usage thérapeutique)</term><term>Infliximab</term><term>Mâle</term><term>Méthotrexate (usage thérapeutique)</term><term>Polyarthrite rhumatoïde (imagerie diagnostique)</term><term>Polyarthrite rhumatoïde (traitement médicamenteux)</term><term>Récepteurs aux facteurs de nécrose tumorale (usage thérapeutique)</term><term>Sensibilité et spécificité</term><term>Sujet âgé</term><term>Synovite (imagerie diagnostique)</term><term>Synovite (traitement médicamenteux)</term><term>Échographie-doppler ()</term><term>Étanercept</term><term>Études prospectives</term><term>Évolution de la maladie</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Tumor Necrosis Factor-alpha</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antibodies, Monoclonal, Humanized</term><term>Antirheumatic Agents</term><term>Immunoglobulin G</term><term>Methotrexate</term><term>Receptors, Tumor Necrosis Factor</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Adalimumab</term><term>Etanercept</term><term>Infliximab</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Facteur de nécrose tumorale alpha</term></keywords><keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Arthritis, Rheumatoid</term><term>Synovitis</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Arthritis, Rheumatoid</term><term>Synovitis</term></keywords><keywords scheme="MESH" qualifier="imagerie diagnostique" xml:lang="fr"><term>Polyarthrite rhumatoïde</term><term>Synovite</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Arthrography</term><term>Ultrasonography, Doppler</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Arthrography</term><term>Ultrasonography, Doppler</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Polyarthrite rhumatoïde</term><term>Synovite</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Anticorps monoclonaux humanisés</term><term>Antirhumatismaux</term><term>Immunoglobuline G</term><term>Méthotrexate</term><term>Récepteurs aux facteurs de nécrose tumorale</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Disease Progression</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Observer Variation</term><term>Prospective Studies</term><term>Sensitivity and Specificity</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adalimumab</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Arthrographie</term><term>Biais de l'observateur</term><term>Femelle</term><term>Humains</term><term>Infliximab</term><term>Mâle</term><term>Sensibilité et spécificité</term><term>Sujet âgé</term><term>Échographie-doppler</term><term>Étanercept</term><term>Études prospectives</term><term>Évolution de la maladie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Our prospective study aimed to demonstrate that the cumulative synovial power Doppler (PD) ultrasound scores correlate with radiographic progression better than conventional measures in patients with rheumatoid arthritis (RA). We also investigated the difference between antirheumatic agents.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24187096</PMID><DateCompleted><Year>2014</Year><Month>08</Month><Day>12</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0315-162X</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><Issue>12</Issue><PubDate><Year>2013</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The Journal of rheumatology</Title><ISOAbbreviation>J. Rheumatol.</ISOAbbreviation></Journal><ArticleTitle>Correlation of radiographic progression with the cumulative activity of synovitis estimated by power Doppler ultrasound in rheumatoid arthritis: difference between patients treated with methotrexate and those treated with biological agents.</ArticleTitle><Pagination><MedlinePgn>1967-76</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3899/jrheum.130556</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Our prospective study aimed to demonstrate that the cumulative synovial power Doppler (PD) ultrasound scores correlate with radiographic progression better than conventional measures in patients with rheumatoid arthritis (RA). We also investigated the difference between antirheumatic agents.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Sixty-nine patients with RA who had recently received either methotrexate (MTX; n = 23), tumor necrosis factor (TNF) antagonists (n = 28), or tocilizumab (TCZ; n = 18) were enrolled. Patients underwent clinical, laboratory, and ultrasonographic assessment at baseline, 12 weeks, and 24 weeks. Radiographic damage was evaluated using van der Heijde modified total Sharp score (TSS) at baseline and 24 weeks.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Fifty-seven patients continued the same treatment regimen for 24 weeks and completed the study, and 21 patients (36.8%) showed radiographic progression during the study period. In all patients, ΔTSS significantly correlated both with cumulative 28-joint Disease Activity Score-C-reactive protein (DAS28-CRP; ρ = 0.342, p = 0.009) and cumulative total PD scores (ρ = 0.357, p = 0.006). In MTX-treated patients, cumulative total PD scores significantly correlated with ΔTSS (ρ = 0.679, p = 0.004), whereas cumulative DAS28-CRP did not (ρ = 0.487, p = 0.056). However, cumulative total PD scores did not correlate with ΔTSS in TNF antagonist-treated or TCZ-treated patients.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our data confirm the evidence that synovial PD activity more accurately reflects active synovial inflammation (which actually causes joint destruction) than do conventional measures in patients treated with MTX. Our data also indicate that TNF antagonists can inhibit short-term radiographic progression in the presence of active synovitis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ikeda</LastName><ForeName>Kei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>From the Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakagomi</LastName><ForeName>Daiki</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Sanayama</LastName><ForeName>Yoshie</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Yamagata</LastName><ForeName>Mieko</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Okubo</LastName><ForeName>Ayako</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Iwamoto</LastName><ForeName>Taro</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Kawashima</LastName><ForeName>Hirotoshi</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Kentaro</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Nakajima</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>11</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>J Rheumatol</MedlineTA><NlmUniqueID>7501984</NlmUniqueID><ISSNLinking>0315-162X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018124">Receptors, Tumor Necrosis Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>B72HH48FLU</RegistryNumber><NameOfSubstance UI="D000069285">Infliximab</NameOfSubstance></Chemical><Chemical><RegistryNumber>FYS6T7F842</RegistryNumber><NameOfSubstance UI="D000068879">Adalimumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>I031V2H011</RegistryNumber><NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>OP401G7OJC</RegistryNumber><NameOfSubstance UI="D000068800">Etanercept</NameOfSubstance></Chemical><Chemical><RegistryNumber>YL5FZ2Y5U1</RegistryNumber><NameOfSubstance UI="D008727">Methotrexate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000068879" MajorTopicYN="N">Adalimumab</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001172" MajorTopicYN="Y">Arthritis, Rheumatoid</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001175" MajorTopicYN="N">Arthrography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068800" MajorTopicYN="N">Etanercept</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069285" MajorTopicYN="N">Infliximab</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008727" MajorTopicYN="N">Methotrexate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015588" MajorTopicYN="N">Observer Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018124" MajorTopicYN="N">Receptors, Tumor Necrosis Factor</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013585" MajorTopicYN="Y">Synovitis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018608" MajorTopicYN="N">Ultrasonography, Doppler</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">RADIOGRAPHY</Keyword><Keyword MajorTopicYN="N">RHEUMATOID ARTHRITIS</Keyword><Keyword MajorTopicYN="N">SYNOVITIS</Keyword><Keyword MajorTopicYN="N">ULTRASONOGRAPHY</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24187096</ArticleId><ArticleId IdType="pii">jrheum.130556</ArticleId><ArticleId IdType="doi">10.3899/jrheum.130556</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001560 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001560 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:24187096
|texte= Correlation of radiographic progression with the cumulative activity of synovitis estimated by power Doppler ultrasound in rheumatoid arthritis: difference between patients treated with methotrexate and those treated with biological agents.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:24187096" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a TocilizumabV1
| This area was generated with Dilib version V0.6.34. |  |